Diabesity Rounds

Orforglipron vs semaglutide

Orforglipron is a once-daily oral small-molecule GLP-1 receptor agonist. Semaglutide is a GLP-1 receptor agonist peptide given as a weekly injection or a daily tablet. This page brings together our reports on each, and on studies that looked at both.

What our reports show

No report we hold compared orforglipron with semaglutide directly. The one report that mentions both, an EMA committee news item, is a regulatory update. It describes orforglipron as an alternative to injectable and other oral GLP-1 receptor agonists. It reports no trial data, and the European Commission decision is pending.

The orforglipron evidence we hold is against placebo or a different drug class. In ATTAIN-J, the mean bodyweight change at week 72 in Japanese adults was -5.9% (6 mg), -8.7% (12 mg) and -7.9% (36 mg), against -0.6% with placebo. In ACHIEVE-2, a sponsor registry entry, HbA1c at week 40 fell by 1.32, 1.74 and 1.73 with three orforglipron doses and by 0.76 with dapagliflozin 10 mg. No formal test result is posted.

The semaglutide reports also come from separate populations. A FLOW post hoc analysis of 3533 adults with CKD and type 2 diabetes found HbA1c differences versus placebo of -0.7% to -1.0% with semaglutide 1.0 mg at Week 104. A registry entry in obesity-related HFpEF with type 2 diabetes reported weight change of -10.2% with semaglutide 2.4 mg and -3.2% with placebo at week 52.

These figures should not be set side by side. The patients differ (Japanese adults with obesity, people on metformin, CKD, HFpEF). So do the comparators, doses, durations (72, 40, 104 and 52 weeks) and endpoints. Two of the four trial reports are registry entries, not peer-reviewed papers. Until a head-to-head trial is reported, these reports cannot show which drug works better or is better tolerated.

Written only from the reports below and checked against them. Updated 13 November 2026.

Studies that looked at both

Orforglipron

Semaglutide

For registered medical practitioners. This page summarises published research and is not advice for individual patients. Last new report 13 November 2026.